Genotech Statistics
Total Valuation
Genotech has a market cap or net worth of KRW 6.13 billion.
Market Cap | 6.13B |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Genotech has 5.60 million shares outstanding.
Current Share Class | 5.60M |
Shares Outstanding | 5.60M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 48.66% |
Owned by Institutions (%) | n/a |
Float | 2.52M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.84 |
PB Ratio | 1.28 |
P/TBV Ratio | 1.29 |
P/FCF Ratio | 48.91 |
P/OCF Ratio | 16.24 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.99, with a Debt / Equity ratio of 1.85.
Current Ratio | 0.99 |
Quick Ratio | 0.49 |
Debt / Equity | 1.85 |
Debt / EBITDA | n/a |
Debt / FCF | 70.91 |
Interest Coverage | -2.64 |
Financial Efficiency
Return on equity (ROE) is -25.60% and return on invested capital (ROIC) is -4.56%.
Return on Equity (ROE) | -25.60% |
Return on Assets (ROA) | -4.12% |
Return on Invested Capital (ROIC) | -4.56% |
Return on Capital Employed (ROCE) | -9.99% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.47 |
Inventory Turnover | 2.13 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.28% in the last 52 weeks. The beta is 0.31, so Genotech's price volatility has been lower than the market average.
Beta (5Y) | 0.31 |
52-Week Price Change | -18.28% |
50-Day Moving Average | 1,173.52 |
200-Day Moving Average | 1,348.22 |
Relative Strength Index (RSI) | 45.22 |
Average Volume (20 Days) | 45 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genotech had revenue of KRW 7.28 billion and -1.32 billion in losses. Loss per share was -280.00.
Revenue | 7.28B |
Gross Profit | 962.09M |
Operating Income | -1.01B |
Pretax Income | -1.32B |
Net Income | -1.32B |
EBITDA | -347.19M |
EBIT | -1.01B |
Loss Per Share | -280.00 |
Balance Sheet
The company has 1.21 billion in cash and 8.89 billion in debt, giving a net cash position of -7.68 billion or -1,371.07 per share.
Cash & Cash Equivalents | 1.21B |
Total Debt | 8.89B |
Net Cash | -7.68B |
Net Cash Per Share | -1,371.07 |
Equity (Book Value) | 4.80B |
Book Value Per Share | 1,017.52 |
Working Capital | -55.69M |
Cash Flow
In the last 12 months, operating cash flow was 377.41 million and capital expenditures -252.05 million, giving a free cash flow of 125.36 million.
Operating Cash Flow | 377.41M |
Capital Expenditures | -252.05M |
Free Cash Flow | 125.36M |
FCF Per Share | 22.39 |
Margins
Gross margin is 13.21%, with operating and profit margins of -13.90% and -18.14%.
Gross Margin | 13.21% |
Operating Margin | -13.90% |
Pretax Margin | -18.14% |
Profit Margin | -18.14% |
EBITDA Margin | -4.77% |
EBIT Margin | -13.90% |
FCF Margin | 1.72% |
Dividends & Yields
Genotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -9.92% |
Shareholder Yield | n/a |
Earnings Yield | -21.55% |
FCF Yield | 2.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Genotech has an Altman Z-Score of -0.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.11 |
Piotroski F-Score | 3 |